T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis

Autologous T lymphocytes genetically engineered to express a murine T cell receptor (TCR) against human carcinoembryonic antigen (CEA) were administered to three patients with metastatic colorectal cancer refractory to standard treatments. All patients experienced profound decreases in serum CEA lev...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Molecular therapy 2011-03, Vol.19 (3), p.620-626
Hauptverfasser: Parkhurst, Maria R, Yang, James C, Langan, Russell C, Dudley, Mark E, Nathan, Debbie-Ann N, Feldman, Steven A, Davis, Jeremy L, Morgan, Richard A, Merino, Maria J, Sherry, Richard M, Hughes, Marybeth S, Kammula, Udai S, Phan, Giao Q, Lim, Ramona M, Wank, Stephen A, Restifo, Nicholas P, Robbins, Paul F, Laurencot, Carolyn M, Rosenberg, Steven A
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Autologous T lymphocytes genetically engineered to express a murine T cell receptor (TCR) against human carcinoembryonic antigen (CEA) were administered to three patients with metastatic colorectal cancer refractory to standard treatments. All patients experienced profound decreases in serum CEA levels (74–99%), and one patient had an objective regression of cancer metastatic to the lung and liver. However, a severe transient inflammatory colitis that represented a dose limiting toxicity was induced in all three patients. This report represents the first example of objective regression of metastatic colorectal cancer mediated by adoptive T cell transfer and illustrates the successful use of a TCR, raised in human leukocyte antigen (HLA) transgenic mice, against a human tumor associated antigen. It also emphasizes the destructive power of small numbers of highly avid T cells and the limitations of using CEA as a target for cancer immunotherapy.
ISSN:1525-0016
1525-0024
DOI:10.1038/mt.2010.272